
NEAT ID INTEGRATION GRANT
7 NEAT ID Integration Grants have been awarded. NEAT ID have also supported junior Doctors travelling to global conferences and provided grants supporting panel meetings. 3 were awarded at the end of 2022. .
What is a NEAT ID Integration Grant?
-
A scientific grant given to a minimum of two countries in collaboration, which includes at least one NEAT ID site.
-
They are preferentially provided to studies which may relate to ongoing NEAT ID trials
-
Cover a wide range of infectious diseases which NEAT ID are interested in, HIV, Hepatitis, MPX, COVID
-
The value of the grant is around 100,000 euros
-
Reviewed by an independent international panel of experts
2022 NEAT ID Integration Grants
Dr Merle Henderson
Imperial College London
Title: Longitudinal changes in plasma neuronal markers in persons with HIV commencing ART.
Status: Ongoing
Dr Linos Vandekerckhove
Ghent university
Title: Feasibility evaluation of anti-HIV Antibody-secreting Chimeric Antigen Receptor T cells as a potential cure in acute seroconverters
Status: Ongoing
Publications: Data demonstrating in vivo secretion of 3BNC117 will be presented as an oral presentation at the International HIV cure and 2000HIV Symposium (https://hivontrafelen.be/nieuws/program1/)
Dr Christoph Boesecke
Bonn University Hospital
Title: NEAT-No-C: A multicenter European cohort on annual HCV incidence in MSM in Europe with an embedded European HCV biobank
Status: Ongoing
2018 NEAT ID Integration Grant
Professor Charles Béguelin Grant 2018
Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland
Kinetics of Hepatitis B Virus markers in treated HIV/HBV-coinfected patients
Publications:
-
Published in Liver International (2023). “Hepatitis Delta infection among persons living with HIV in Europe – Published in Liver International 2023” https://pubmed.ncbi.nlm.nih.gov/36625770/
-
Published in Frontiers in Medicine (2022). “Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection” https://www.frontiersin.org/articles/10.3389/fmed.2022.988356/full
-
Published in CID (2022). “Hepatitis B Virus replication during tenofovir therapy is frequent in human immunodeficiency virus/HBV coinfection.” https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciac823/6761485?redirectedFrom=fulltext
2016 NEAT ID Integration Grant
Dr Christoph Boeseck Grant 2016
Bonn University Hospital NEAT 001 Follow Up
Re-infection and DAA-based treatment uptake in acute HCV coinfection within the European acute HCV cohort PROBE-C
Publications:
-
Published in Clinical Infectious Diseases. “Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus–Positive Men Who Have Sex With Men (PROBE-C Study)” https://pubmed.ncbi.nlm.nih.gov/36004410/
Using Partial Data:
2. Published In Clinical Infectious Diseases. “Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era” https://pubmed.ncbi.nlm.nih.gov/31562816/
3. Published in Clinical Infectious Diseases. “Clinical Infectious Diseases publication containing partial data from Probe-C Cohort”
Has been awarded NEAT ID Integration Grant 2022 for follow up.
Dr Jose Arribas Grant 2016
Foundation for Biomedical Research of University, Hospital La Paz, Madrid
Telomere length changes after darunavir-ritonavir combined with either raltegravir or tenofovir- emtricitabine in antiretroviral-naive adults with HIV-1: a sub-study of the NEAT001/ANRS143
Publications:
-
Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. J Infect Dis. 2018 Oct 5;218(10):1523-1530. IF 5.60
-
Alejos B, Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Schwimmer C, Bernardino JI, Rodes B, Esser S, Goujard C, Sarmento-Castro R, De Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ANRS 143 Study Group. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial. HIV Med. 2019 Nov;20(10):691-698. IF 3.556
Prof. Gilles Wandeler Grant 2016
University of Bern
Multi-cohort study to inform hepatocellular carcinoma screening strategies in HIV/HBV-coinfected individuals on tenofovir-containing therapy
Publications:
-
Published in J Hepatol (2019). “Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies” https://pubmed.ncbi.nlm.nih.gov/30965070/
-
Published in J Hepatol (2023). “External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. https://pubmed.ncbi.nlm.nih.gov/36690280/
-
Oral abtrsact presented at CROI 2023. “External validation of the PAGE-B score to estimate the risk of hepatocellular carcinoma in persons living with HIV and hepatitis B”
Research Grants
Prof Esteban Martinez
Hospital Clinic & University of Barcelona
NEAT 022 Sub-Studies: An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression
Publications:
-
Published in J Antimicrob Chemother (2023). “Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.” 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. PMID: 37539492
-
Published in CID (2023) “Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.” 5;77(7):991-1009. doi: 10.1093/cid/ciad297. PMID: 37207617
-
Published in CID (2023) “Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.” 76(5):861-870. doi: 10.1093/cid/ciac827. PMID: 36259527 Clinical Trial.
-
Published in J Antimicrob Chemother (2022). “Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.” 29;77(7):1980-1988. doi: 10.1093/jac/dkac117. PMID: 35411401 Clinical Trial.
-
Published in J Antimicrob Chemother (2021). “Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.” 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. PMID: 34120186 Clinical Trial.
-
Published in J Antimicrob Chemother (2020). “Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.” 1;75(11):3334-3343. doi: 10.1093/jac/dkaa292.
PMID: 32737482 Clinical Trial.